Optimizing Patient Selection & Prediction of Therapy Efficacy in
Clinical Trials with ctDNA

Tuesday June 14 | 6pm - 8pm ET | Boston, MA | In-Person Event Only

Please Note: This event is taking place in-person only, and online attendance will not be available.

This is an exclusive event created to provide senior pharma leaders with the opportunity to hear from fellow pharma stakeholders and researchers on how they are using circulating tumor DNA (ctDNA) to optimize and accelerate oncology therapeutic development. Discover the latest biomarker strategies leveraging ctDNA to:

 

    • Stratify & enrich for patients most likely to benefit from additional therapy to maximize treatment benefit and decrease the necessary study size
    • Monitor therapy response for early prediction of therapy efficacy to support program prioritization
    • Support accelerated approval of new therapeutics as a potential surrogate endpoint

 

Join us for an insightful panel discussion among pharma Directors, VPs and Functional Heads within the translational, clinical development, and diagnostics arenas, and connect over a few appetizers and drinks!

EXPERT SPEAKERS

two-river-logo@2x (002)
bicycle therapeutics logo (002)
Natera (002)

Please Note: This event is taking place in-person only, and online attendance will not be available.

This event is reserved for decision makers and senior representatives in the biopharma community with therapies in their pipeline. By registering online, you are submitting your interest in this exclusive networking meeting, and a colleague will be in touch upon registering to confirm or decline your place based on the mentioned criteria.

Having trouble registering? Email: info@hansonwade.com

*Attendance is subject to final approval from the event organizers

VENUE & AGENDA DETAILS

The Ritz – Carlton

10 Avery Street, Boston, MA 02111, United States

Check Out Their Website Here

Agenda: Optimizing Patient Selection & Prediction of Therapy Efficacy in Clinical Trials with ctDNA

Tuesday, June 14

6:00 pm Doors Open – Registration & Welcome Reception

6:30 pm Opening Remarks & Introduction

6:35 pm Interactive Panel Discussion & Q&A: Trends & Opportunities for ctDNA in Clinical Trials

Synopsis

• Hear biopharma and academic perspectives on key challenges in oncology drug development that ctDNA seeks to address
• Discuss how ctDNA has been used to stratify and enrich for clinical trial cohorts and support early assessment of therapy efficacy today, and how this is expected to evolve in the future
• Evaluate opportunities to leverage ctDNA to support program prioritization, secure additional funding, and optimize clinical trial design

7:15 pm Networking & Drinks

Synopsis

Informal and exclusive opportunity to engage with senior pharma leaders and researchers interested in ctDNA and oncology clinical trial innovations

8:00 pm End of Natera Engager

ABOUT OUR HOST

Natera_Logo (1)

Natera has developed Signatera, a tumor-informed circulating tumor DNA (ctDNA) test, capable of detecting the presence of molecular residual disease (MRD) down to a single tumor molecule in a tube of blood.
With 20+ peer-reviewed publications and 60+ presentations, Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Signatera is being used in multiple prospective studies, received CMS Local Coverage Determination for immunotherapy monitoring and Stage II-IV colorectal cancer, and is available to biopharmaceutical customers and clinicians globally.

Look deeper at:

www.natera.com/clinical-trials